1 / 22

Current status of Thalassaemia major

Current status of Thalassaemia major. Chi-Kong Li, MD. Chief, Division of Haematology/Oncology/BMT, Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong. Modern Transfusion Management of Thalassaemia Major. Regular transfusion, maintain Hb >9.5 g/dl.

mondragon
Download Presentation

Current status of Thalassaemia major

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Current status of Thalassaemia major Chi-Kong Li, MD. Chief, Division of Haematology/Oncology/BMT, Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong.

  2. Modern Transfusion Management of Thalassaemia Major • Regular transfusion, maintain Hb >9.5 g/dl. • Safe transfusion : • Leucocyte removal filter (pre-storage), <5x106 Transfusion reaction, alloimmunisation • Screening for infectious disease. • 2-6 weeks interval to suppress bone marrow activity, promote normal growth.

  3. Iron overload • 1.16 mg iron in 1 ml pure red cells (Hct) • iron accumulation proportional to volume of blood transfused, • a 30 kg child may receive 4-8 gm iron /yr, • increase iron absorption from gut, • normal adult total body iron 55 mg/kg, (4.0gm) • no excretory pathway for excessive iron

  4. Morbidity in Thalassaemia Major Patinets (I) • Endocrine: • Hypogonadism : 55% >15 years. • Diabetes Mellitus : 6-8%. • Hypothyroidism (Subclinical) : 11% • Hypoparathyroidism : 5% • Short Stature : (<3%, corrected for parental height). • Multiple factors 25-50%. (Endocrine and bone changes)

  5. Morbidity in Thalassaemia Major Patinets (II) • Liver disease: HCV infection (Italy) • HCV +ve >14 years: 88% <14 years: 28% • 75% showed chronic hepatitis. • Cardiac disease: • Symptomatic 8.5% • Echocardiographic abnormalies 20-60%.

  6. Menstruation Problems in Thalassaemia Females • Primary amenorrhoea 50% • Secondary amenorrhoea 20% • Memarche and regular menses 30%

  7. Figure 1: KAPLAN MEIER SURVIVAL ANALYSIS ON 257 CONSECUTIVE TRANSFUSION-DEPENDENT BETA THALASSEMIC PATIENTS IN TORINO H = 147 L = 64 Cox’s F test = 1.7 p<0.03 Piga A, Torino, Italy BMT, 1997, 19(S2):11-13.

  8. Current Status in Hong Kong : Thalassaemia Major • 293 patients • Age : 0-5 yr : 18 (6.1%) 6-10 yr : 45 (15%) 11-15 yr : 71 (24%) 16-20 yr : 69 (23%) 21-30 yr : 89 (30%) • Regular chelation started since early 1980s.

  9. Morbidity among H.K. Thalassaemia Patients Heart failure : 21 patients (7.3%) Diabetes mellitus: 18 patients (6%) Hepatitis B carrier: 3 (1%) Hepatitis C carrier: 47 (16%)

  10. Diabetes in TM

  11. Complications of TM according to age

  12. Endocrine complications (PWH, QEH, PMH, N=232) HKMJ 2002, 8:255-60

  13. Ht Standard Deviation Score HKMJ 2002, 8:255-60

  14. Bone diseases in TM • Desferrioxamine induced in properly transfused and chelated patients, • metaphyseal sclerosis, platyspondyly, bone infarct. • plain X-ray, ultrasound, MRI. • 16 of 41 patients showed varying degree of dysplasia. Pediatr Radiol 2002, 32:492-7

  15. Death : 1996 -2000 • 17 deaths over past 5 years • 11 due to cardiac diseases • 5 died as complication of bone marrow transplantation • 1 died after klebsiella meningitis

  16. BMT for Thalassaemias • Eradicate the pathological marrow by mega-dose chemotherapy. • Replacement of a new healthy haematopoietic system (HLA-Identical sibling). • Transfusion independent. • Free from transfusion related complications. • Improved quality of life-physical and psychosocial.

  17. Disease Free Survival Thalassaemia after BMT 1.0 .9 .8 .7 .6 Probability of Survival .5 .4 .3 .2 Survival Function .1 DFS 84% 0.0 0 20 40 60 80 100 Duration of follow up in months BMT 2002, 29:101-5

  18. Disease free survival according to age 1.0 90% .9 86% .8 .7 62.5% Age at BMT .6 Probability of survival 10-16 yr (n-=15) .5 .4 > 16 yr (n=8) .3 .2 < 10 yr (n=21) .1 0.0 0 20 40 60 80 100 Duration of follow up in months BMT 2002, 29:101-5.

  19. Disease Free survival according to Class 100% 1.0 .9 84% .8 .7 CLASS .6 57% Class 3 (n=7) Probability of Survival .5 .4 Class 2 (n=25) .3 .2 Class 1 (n=8) .1 0.0 0 20 40 60 80 100 Follow up in months (02/2000)

  20. Changes of Ht after BMT: PWH experience Ped Hematol Oncol 2004, 21:411-9.

  21. Conventional Treatment • Improved survival, • still with complications from iron overload and treatment, • poor compliance not uncommon esp at adolescent age group, • mortality does happen, life expectancy not sure (>40 years) • quality of life sub-optimal.

  22. Future of Management of Thalassaemia major • Oral chelators - as second line treatment, not first line treatment yet.. • More safe BMT • Extension of BMT to alternative donors: unrelated bone marrow donor or cord blood. • Gene therapy.

More Related